¼¼°èÀÇ Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, Åõ¿© °æ·Îº°, ÀûÀÀÁõº° - ¿¹Ãø(2025-2030³â)
Anti-vascular Endothelial Growth Factor Therapeutics Market by Therapeutic Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors), Route of Administration (Intravitreal Injections, Oral Administration), Indication - Global Forecast 2025-2030
»óǰÄÚµå : 1602810
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 191 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀåÀº 2023³â¿¡ 84¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 90¾ï 1,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, CAGR 8.85%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 153¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á´Â ³ëÈ­ Ȳ¹Ý º¯¼ºÁõ(AMD), ´ç´¢º´¼º ¸Á¸·Áõ, ƯÁ¤ ¾Ï µî Ç÷°üÀÇ ÀÌ»ó Áõ½Ä°ú °ü·ÃµÈ ÁúȯÀÇ Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±× ¹üÀ§´Â Ç÷°ü ½Å»ý¿¡ °ü¿©ÇÏ´Â VEGF ´Ü¹éÁúÀ» ¾ïÁ¦Çϰí Áúº´ÀÇ ÁøÇàÀ» ¸·´Â °ÍÀÔ´Ï´Ù. Àα¸ÀÇ °í·ÉÈ­¿¡ µû¶ó Ç÷°ü°ú °ü·ÃµÈ Áúº´ÀÇ À¯º´·üÀÌ »ó½ÂÇÔ¿¡ µû¶ó Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·áÁ¦¿Í °°Àº È¿°úÀûÀÎ Ä¡·á¹ýÀÇ Çʿ伺ÀÌ µÎµå·¯Áö°í ÀÖ½À´Ï´Ù. ÀÌ Ä¡·áÁ¦´Â ÁÖ·Î ¾È°ú¿Í Á¾¾ç°ú¿¡ ÀÀ¿ëµÇ¾î º´¿ø, Ŭ¸®´Ð, Àü¹® ÇコÄÉ¾î ¼¾ÅÍ µîÀÇ ÃÖÁ¾ »ç¿ëÀÚ¿¡°Ô ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ´ë»ó ÁúȯÀÇ ÀÌȯÀ² Áõ°¡, »ý¹° Á¦Á¦ÀÇ Áøº¸, À¯¸Á È­ÇÕ¹°ÀÇ Ãæ½ÇÇÑ ÆÄÀÌÇÁ¶óÀÎ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ß, ½ÅÈï±¹ ½ÃÀå¿¡¼­ÀÇ Áö¸®Àû È®´ë, Ä¡·á ¼º°ú¸¦ ÃÖÀûÈ­Çϱâ À§ÇÑ °Ô³ðÀû ÀλçÀÌÆ®¸¦ Ȱ¿ëÇÑ °³º°È­ ÀÇ·á Á¢±Ù¹ý¿¡ ÁÖ·ÂÇÔÀ¸·Î½á ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ¸¦ ÀâÀ» ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 84¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 90¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 153¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 8.85%

±×·¯³ª ÀÌ ½ÃÀåÀº ³ôÀº Ä¡·áºñ, ¹ÙÀÌ¿À½Ã¹Ð·¯ °æÀïÀ¸·Î À̾îÁö´Â ƯÇã ¸¸·á, Àå±â Ä¡·á¿¡ µû¸¥ ÀáÀçÀûÀÎ ºÎÀÛ¿ë µîÀÇ °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦»óÀÇ ÇãµéÀ̳ª »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶ÀÇ º¹ÀâÇÔÀº, ½ÃÀå È®´ëÀÇ »õ·Î¿î °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¿¡µµ ºÒ±¸ÇÏ°í ±â¼ú Çõ½ÅÀº ¿©ÀüÈ÷ Áß¿äÇÕ´Ï´Ù. ¼­¹æ¼º Á¦Á¦, º´¿ë ¿ä¹ý, À¯¸® ü³» Áֻ糪 ¾È³» ÀÓÇöõÆ® µîÀÇ ½Å±Ô Àü´Þ ½Ã½ºÅÛ°ú °°Àº ºÐ¾ß´Â À¯¸ÁÇÑ ¿¬±¸ ¼ö´ÜÀÌ µË´Ï´Ù. °Ô´Ù°¡ Ä¡·á È¿°ú¸¦ ¸ð´ÏÅ͸µÇÏ´Â ¿ø°ÝÀÇ·á¿Í °°Àº µðÁöÅÐ ±â¼úÀÇ ÅëÇÕÀº ȯÀÚ °ü¸®¸¦ °­È­Çϰí ÇコÄÉ¾î ºÎ´ãÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¿ªµ¿ÀûÀÎ °æÀï, ²÷ÀÓ¾ø´Â Áøº¸, ±×¸®°í ÀϹÝÀûÀ¸·Î ¸¸³ª´Â À庮¿¡ ´ëÇÑ Áö¼Ó °¡´ÉÇÑ ÇØ°áÃ¥¿¡ ´ëÇÑ °­ÇÑ µÞ¹ÞħÀ¸·Î Ư¡Áö¾îÁý´Ï´Ù. Á¦¾àȸ»ç, Çмú±â°ü, ¹ÙÀÌ¿ÀÅ×Å©³î·ÎÁö ±â¾÷°£ÀÇ °øµ¿¿¬±¸¸¦ Áß½ÃÇÔÀ¸·Î½á Áúȯ ¸ÞÄ¿´ÏÁòÀÇ ÇØ¸íÀ̳ª º¸´Ù È¿°úÀûÀÎ anti-VEGF Ä¡·áÀÇ ¿¬±¸°³¹ß¿¡ À־ µ¹ÆÄ¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» ÆÄ¾ÇÇÏ°í ±ÔÁ¦ »óȲÀÇ º¯È­¿¡ ´ëÀÀÇÔÀ¸·Î½á ±â¾÷Àº ÀÌ ÁøÈ­ÇÏ´Â Ä¡·á ¿µ¿ª¿¡¼­ÀÇ ´ëÆøÀûÀÎ ¼ºÀåÀ» Àü·«ÀûÀ¸·Î ÀÚ¸®¸Å±èÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces : Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎÀÇ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ±âÈ£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ» ³»´Ùº» Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÀÔÁö¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇöÀç ÁõÁøÀ» ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ Áú¹®¿¡ ÀÀ´äÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð ¹× ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À² ¹× °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°

Á¦7Àå Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°

Á¦8Àå Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå : ÀûÀÀÁõº°

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(anti-VEGF) Ä¡·á ½ÃÀå

Á¦12Àå °æÀï ±¸µµ

±â¾÷ ¸ñ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Anti-vascular Endothelial Growth Factor Therapeutics Market was valued at USD 8.49 billion in 2023, expected to reach USD 9.01 billion in 2024, and is projected to grow at a CAGR of 8.85%, to USD 15.38 billion by 2030.

Anti-vascular endothelial growth factor (VEGF) therapeutics play a critical role in treating conditions related to abnormal blood vessel growth, such as age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers. Their scope involves inhibiting VEGF proteins responsible for angiogenesis, thus preventing disease progression. As the prevalence of vascular-related conditions escalates with an aging population, the necessity for effective treatments like anti-VEGF therapeutics has become more pronounced. These therapies find applications primarily in ophthalmology and oncology, serving end-users such as hospitals, clinics, and specialized healthcare centers. Key growth influencers include an increasing incidence of target disorders, advancements in biologics, and a robust pipeline of promising compounds. Companies can seize potential opportunities by focusing on biosimilars development, geographic expansion in emerging markets, and personalized medicine approaches, leveraging genomic insights to optimize therapeutic outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 8.49 billion
Estimated Year [2024] USD 9.01 billion
Forecast Year [2030] USD 15.38 billion
CAGR (%) 8.85%

However, the market faces challenges, including high treatment costs, patent expiration leading to biosimilar competition, and potential adverse effects associated with long-term therapy use. Regulatory hurdles and the complexity of biologic drug manufacturing further challenge market expansion. Despite these impediments, innovation remains crucial; areas like extended-release formulations, combination therapies, and novel delivery systems such as intravitreal injections or ocular implants offer promising research avenues. Moreover, digital technology integration, like telemedicine for monitoring treatment efficacy, can enhance patient management and reduce healthcare burdens. The market is marked by dynamic competition, constant advancements, and a strong push towards sustainable solutions to commonly encountered barriers. Emphasizing collaborative research between pharmaceutical companies, academic institutions, and biotech firms can spur breakthroughs in understanding disease mechanisms and developing more effective anti-VEGF therapies. By staying attuned to these trends and adaptable to changing regulatory landscapes, businesses can strategically position themselves for substantial growth in this evolving therapeutic domain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-vascular Endothelial Growth Factor Therapeutics Market

The Anti-vascular Endothelial Growth Factor Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Anti-vascular Endothelial Growth Factor Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-vascular Endothelial Growth Factor Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-vascular Endothelial Growth Factor Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-vascular Endothelial Growth Factor Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-vascular Endothelial Growth Factor Therapeutics Market

A detailed market share analysis in the Anti-vascular Endothelial Growth Factor Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-vascular Endothelial Growth Factor Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-vascular Endothelial Growth Factor Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-vascular Endothelial Growth Factor Therapeutics Market

A strategic analysis of the Anti-vascular Endothelial Growth Factor Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-vascular Endothelial Growth Factor Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alteogen Inc., Amgen Inc., Arechar Healthcare, Aurobindo Pharma, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Cipla Ltd., Coherus BioSciences, Inc., Delphis Pharmaceutical India, F. Hoffmann-La Roche AG, Hetero Healthcare Limited, Intas Pharmaceuticals Ltd., Natco Pharma Limited, Novartis AG, Pfenex Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Samsung Bioepis, Sandoz Canada Incorporated, Shilpa Medicare Ltd., Sun Pharmaceutical Industries Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Xbrane Biopharma.

Market Segmentation & Coverage

This research report categorizes the Anti-vascular Endothelial Growth Factor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Therapeutic Type

7. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Route of Administration

8. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Indication

9. Americas Anti-vascular Endothelial Growth Factor Therapeutics Market

10. Asia-Pacific Anti-vascular Endothelial Growth Factor Therapeutics Market

11. Europe, Middle East & Africa Anti-vascular Endothelial Growth Factor Therapeutics Market

12. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â